2022
DOI: 10.7759/cureus.31092
|View full text |Cite
|
Sign up to set email alerts
|

COVID-19 Exposure Unmasking Systemic Amyloidosis With Hepatic Predominance

Abstract: Amyloidosis is characterized by depositing insoluble fibrillar proteins that misfold into beta-pleated sheets. This phenomenon occurs on a systemic or local level and may interfere with the function of various organs, including the heart, kidneys, and liver. Among those presenting with amyloidosis, hepatic, gastrointestinal, renal, cardiac, vitreous, and immunological involvement may occur. These manifestations are linked to several clinical presentations, varying from abdominal pain and hepatomegaly to restri… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(2 citation statements)
references
References 11 publications
0
2
0
Order By: Relevance
“…The SAA1 i.e. the AA precursor protein is synthesized in the liver and could be triggered by COVID-19 infection and associated with AL-amyloid seeds [ 138 ]. This case would strengthen the hypothesis of AA amyloidosis is a factor causing systemic complications after COVID-19 disease [ 139 ].…”
Section: Covid-19 Sequelae With Similarities and Possible Connections...mentioning
confidence: 99%
“…The SAA1 i.e. the AA precursor protein is synthesized in the liver and could be triggered by COVID-19 infection and associated with AL-amyloid seeds [ 138 ]. This case would strengthen the hypothesis of AA amyloidosis is a factor causing systemic complications after COVID-19 disease [ 139 ].…”
Section: Covid-19 Sequelae With Similarities and Possible Connections...mentioning
confidence: 99%
“…It is well known that SAA lies at the center of AA amyloidosis pathogenesis, so it could be expected that any elevation of serum SAA can accelerate the progression of amyloidosis in patients with this disease. Such an assumption was valid during the COVID-19 infection, where the rise in SAA levels worsened the existing AA amyloidosis (55). In patients without amyloidosis, there are some indications that SARS-CoV-2 envelope protein can speed up the formation of SAA amyloid.…”
Section: Serum Amyloid a And Amyloidosis In Covid-19mentioning
confidence: 99%